GUIDELINES
Protocol for the development of Polish clinical guidelines for the management of patients with systemic lupus erythematosus
More details
Hide details
1
Department of Rheumatology, Medical University of Lodz, Poland
2
Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
3
Department of Rheumatology, Collegium Medicum, University of Warmia and Mazury, Poland
4
Department of Rheumatology and Immunology, Andrzej Frycz Modrzewski University, Krakow, Poland
5
Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Ustron, Poland
6
Department and Clinic of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland
7
Department of Paediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
8
Department of Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
9
Chair of Epidemiology and Preventive Medicine, Collegium Medicum, Jagiellonian University, Krakow, Poland
10
Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
11
Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Poland
12
Department of Neurology, Medical University of Lodz, Poland
Online publication date: 2024-12-30
Corresponding author
Joanna Makowska
Department of Rheumatology, Medical University of Lodz, 113 Stefana Żeromskiego St., 90-543 Lodz, Poland
KEYWORDS
ABSTRACT
Introduction:
Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease that causes multi-organ inflammation and damage. Left untreated or inadequately managed, SLE can lead to severe organ dysfunction, disability, and reduced quality of life. In Poland, the absence of standardized, evidence-based clinical guidelines tailored to local resources and practices has created inconsistencies in SLE management. The purpose of these guidelines is to provide clear, evidence-based recommendations for the treatment and management of adult patients with SLE in the Polish healthcare system. These recommendations aim to align clinical practices with international standards, optimize treatment strategies, standardize patient care, and improve health outcomes while guiding healthcare policy.
Material and Methods:
The adaptation process follows the ADAPTE Collaboration guidelines, the GRADE methodology, and the Evidence to Decision (ETD) framework. An interdisciplinary Working Group (WG), comprising experienced rheumatologists, organ-specific specialists, young rheumatologists, and a patient representative, will develop the guidelines. Key steps will include: 1) creation of clinical questions using the PICO format; 2) systematic search of relevant international guidelines (EULAR, ACR) and national sources; 3) evaluation of identified guidelines using the AGREE II instrument to ensure methodological quality; 4) formulation of recommendations through consensus-based discussions, addressing clinical treatment, monitoring, and care organization.
Scope and implementation:
The guidelines cover pharmacological interventions for SLE, including hydroxychloroquine, glucocorticosteroids, immunosuppressive drugs biologics. Specific focus areas include treatment of organ-specific manifestations, management during pregnancy, treatment of disease flares, maintenance therapy, monitoring, and comorbidity management. The finalized document will undergo external review and be published in both Polish (on the Polish Society for Rheumatology website) and English (in the journal Reumatologia) as open access. Implementation strategies will include dissemination through scientific journals, presentations at conferences.
Conclusions:
These guidelines aim to provide a standardized framework for SLE management in Poland. By implementing evidence-based recommendations, they will support healthcare providers in improving patient outcomes, optimizing resource allocation, and addressing the unique challenges of SLE within the Polish healthcare system.
REFERENCES (13)
1.
Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet 2024; 403: 2326–2338, DOI: 10.1016/S0140-6736(24)00398-2.
2.
Sharma U. The SLE Conundrum: A Comprehensive Analysis of Pathogenesis, Recent Developments, and the Future of Therapeutic Interventions. Crit Rev Immunol 2025; 45: 41–54, DOI: 10.1615/CritRevImmunol.2024053504.
3.
Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021; 17: 515–532, DOI: 10.1038/s41584-021-00668-1.
4.
Krajewski R, Maciorowska K, Rychert A, Wysoczański W. Adaptacja wytycznych: pakiet narzędzi. Polskie tłumaczenie podręcznika ADAPTE. ADAPTE Collaboration. Available at:
https://www.aotm.gov.pl/wp-con....
5.
The ADAPTE Collaboration. (2009) The ADAPTE Process: Resource Toolkit for Guideline Adaptation. Version 2.0. The ADAPTE Collaboration. Available at:
http://www.g-i-n.net.
6.
Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380–382, DOI: 10.1016/j.jclinepi.2010.09.011.
7.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008, DOI: 10.1136/bmj.j4008.
8.
Alonso-Coello P, Schünemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 2016; 353: i2016, DOI: 10.1136/bmj.i2016.
9.
Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016; 353: i2089, DOI: 10.1136/bmj.i2089.
10.
Schünemann HJ, Wiercioch W, Brozek J, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 2017; 81: 101–110, DOI: 10.1016/j.jclinepi.2016.09.009.
11.
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839–E842, DOI: 10.1503/cmaj.090449.
12.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151–1159, DOI: 10.1136/annrheumdis-2018-214819.
13.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686, DOI: 10.1002/art.34473.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.